SAN
DIEGO and HERCULES,
Calif., Feb. 8, 2023 /PRNewswire/ -- Element
Biosciences, Inc. — the developer of an innovative DNA sequencing
platform disrupting genomics — and Bio-Rad Laboratories, Inc.
(NYSE: BIO and BIOb), a global leader in life science research and
clinical diagnostic products, today announced a partnership to
demonstrate the capabilities of the Bio-Rad SEQuoia RNA Sequencing
Library Preparation portfolio on the Element AVITI™ Benchtop
Sequencer.
The Element AVITI Sequencing Platform's novel Avidity Sequencing
chemistry can be easily adapted for use with the Bio-Rad SEQuoia
Complete Stranded RNA Library Prep Kit and the SEQuoia Express
Stranded RNA Library Prep Kit to obtain RNA sequencing accuracy and
repeatability among samples and different RNA inputs.
The SEQuoia Complete Stranded RNA Library Prep Kit offers
unbiased transcriptome profiling during RNA sequencing by capturing
a broad range of RNA subtypes in a single workflow, whether using
low or high input RNA. The SEQuoia Express Stranded RNA Library
Prep Kit offers the additional benefit of a highly efficient 3-tube
workflow for detection of long RNAs that can be completed in only 3
hours.
The Element AVITI System, a benchtop sequencer with excellent
performance, cost savings, and flexibility, combines a simple
workflow with exceptional data quality. For enhanced experiment
design freedom, the AVITI System features two flow cells, each
operating independently, while maintaining the option to deliver up
to 2 billion reads of combined sequencing output.
Recent collaborative studies show high compatibility and
performance for RNA sequencing using SEQuoia library preparation
chemistries on the Element AVITI System. Bio-Rad will present the
results of this collaboration at the Advances in Genome Biology and
Technology (AGBT) General Meeting in Hollywood, Florida, on Thursday, February 9, at 8:00 AM in Presidential Suite 3131 of the
Diplomat Resort Hotel.
"The seamless integration of Element's sequencing technology
with Bio-Rad's SEQuoia portfolio helps enable cost-effective,
flexible, and high-quality sequencing data for our customers," said
Shawn Levy, Chief Scientific Officer
and Senior Vice President of Applications, Element Biosciences.
"We are excited to work with Element to provide RNA library
preparation chemistries offering high performance for a range of
sample types. The collaboration with Element will ensure that our
customers can now access this new sequencing platform in a
ready-to-use format," said Steven
Blakely, Senior Director for the Gene Expression Business,
Bio-Rad.
Please visit bio-rad.com/NGSAGBT2023 to learn more about the
SEQuoia RNA-Seq Library Preparation Kits.
BIO-RAD and SEQuoia are trademarks of Bio-Rad Laboratories in
certain jurisdictions. All trademarks used herein are the property
of their respective owners.
About Bio-Rad
Bio-Rad Laboratories, Inc. (NYSE: BIO
and BIOb) is a global leader in developing, manufacturing, and
marketing a broad range of innovative products for the life science
research and clinical diagnostic markets. With 70 years of focus on
quality and customer service, our products advance the scientific
discovery process and improve healthcare. Our customers are
universities, research institutions, hospitals, biotechnology and
pharmaceutical companies, as well as public health and commercial
laboratories including food safety and environmental quality
testing facilities. Based in Hercules,
California, Bio-Rad has a global network of operations with
approximately 8,200 employees worldwide and $2.9 billion in revenues in 2021. For more
information, please visit bio-rad.com.
About Element Biosciences, Inc.
Element Biosciences
is a multi-disciplinary life science company currently focused on
developing disruptive DNA sequencing technology for research and
diagnostic markets. Through innovating every fundamental element of
a sequencing system, Element empowers customers with affordable,
high-quality data and an improved user experience, which in turn
will accelerate scientific discoveries and broaden the use of
genomic medicine. To learn more about Element, please visit
www.elementbiosciences.com.
Bio-Rad Forward Looking Statements:
This release may be deemed to contain certain forward-looking
statements within the meaning of the Private Securities Litigation
Reform Act of 1995. These forward-looking statements include,
without limitation, statements we make regarding our products and
our expectations about our products. Forward-looking statements
generally can be identified by the use of forward-looking
terminology such as "plan", "believe," "expect," "anticipate,"
"may," "will," "intend," "estimate," "continue," or similar
expressions or the negative of those terms or expressions, although
not all forward-looking statements contain these words. Such
statements involve risks and uncertainties, which could cause
actual results to vary materially from those expressed in or
indicated by the forward-looking statements. These risks and
uncertainties include the duration and severity of the COVID-19
pandemic, supply chain risks, our ability to develop and market new
or improved products, our ability to compete effectively,
international legal and regulatory risks, and product quality and
liability issues. For further information regarding our risks and
uncertainties, please refer to the "Risk Factors" and "Management's
Discussion and Analysis of Financial Condition and Results of
Operation" in Bio-Rad's public reports filed with the Securities
and Exchange Commission, including our most recent Annual Report on
Form 10-K and our Quarterly Reports on Form 10-Q. Bio-Rad cautions
you not to place undue reliance on forward-looking statements,
which reflect an analysis only and speak only as of the date
hereof. We disclaim any obligation to update these forward-looking
statements.
Element Media Contact:
Kristi
Heim
Element Biosciences
Kristi.Heim@elembio.com
Bio-Rad Media Contacts:
Bio-Rad Laboratories,
Inc.
Katrina Academia, Inbound Marketing Manager
+1 510-356-7909
Katrina_academia@bio-rad.com
Zyme Communications
Esmé Walters
+44 (0) 7737 543244
esme.walters@zymecommunications.com
View original content to download
multimedia:https://www.prnewswire.com/news-releases/element-biosciences-and-bio-rad-partner-to-deliver-seamless-rna-sequencing-workflow-between-elements-aviti-system-and-bio-rads-sequoia-express-and-sequoia-complete-stranded-rna-library-prep-kits-301741528.html
SOURCE Element Biosciences